Prescient Therapeutics Investor Briefing – 11 August

August 11, 2021

Prescient Therapeutics Investor Briefing – 11 August

Prescient Therapeutics (ASX: PTX) Webcast Replay

11th August, 2021

Prescient Therapeutics (ASX: PTX)  CEO and MD Steven Yatomi-Clarke discusses the encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200, and providea a company update.

Recorded on 11 August 2021 at 11am (AEST).

Join the next Prescient Therapeutics webcast 

Speak to the Reach Markets team


Steven Yatomi-Clarke

Chief Executive Officer - Prescient Therapeutics (ASX: PTX)

Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also providing new tools for clinicians in combating cancer. Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.